

Akseli Hemminki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1006978/publications.pdf>

Version: 2024-02-01

215
papers

10,828
citations

44069

48
h-index

43889

91
g-index

217
all docs

217
docs citations

217
times ranked

10500
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence trends in lung and bladder cancers in the Nordic Countries before and after the smoking epidemic. <i>European Journal of Cancer Prevention</i> , 2022, 31, 228-234.	1.3	9
2	Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1. <i>Oncolmunology</i> , 2022, 11, 2028960.	4.6	14
3	Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years. <i>PLoS ONE</i> , 2022, 17, e0261124.	2.5	4
4	Oncolytic adenovirus decreases the proportion of TIM-3 ⁺ subset of tumor-infiltrating CD8 ⁺ T cells with correlation to improved survival in patients with cancer. , 2022, 10, e003490.		10
5	Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 794251.	4.8	16
6	Long-term incidence and survival trends in cancer of the gallbladder and extrahepatic bile ducts in Denmark, Finland, Norway and Sweden with etiological implications related to Thorotrast. <i>International Journal of Cancer</i> , 2022, 151, 200-208.	5.1	7
7	Familial Risks for Liver, Gallbladder and Bile Duct Cancers and for Their Risk Factors in Sweden, a Low-Incidence Country. <i>Cancers</i> , 2022, 14, 1938.	3.7	5
8	Long-term incidence in hepatocellular carcinoma and intrahepatic bile duct cancer in Denmark, Finland, Norway and Sweden, role of Thorotrast?. <i>International Journal of Cancer</i> , 2022, 151, 510-517.	5.1	4
9	Cervical, vaginal and vulvar cancer incidence and survival trends in Denmark, Finland, Norway and Sweden with implications to treatment. <i>BMC Cancer</i> , 2022, 22, 456.	2.6	9
10	First-in-human clinical trial of an oncolytic adenovirus armed with TNF α and IL-2 in patients with advanced melanoma receiving adoptive cell transfer of tumor-infiltrating lymphocytes.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9590-TPS9590.	1.6	1
11	Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression. <i>Oncolmunology</i> , 2022, 11, .	4.6	20
12	Oncolytic Adenovirus Type 3 Coding for CD40L Facilitates Dendritic Cell Therapy of Prostate Cancer in Humanized Mice and Patient Samples. <i>Human Gene Therapy</i> , 2021, 32, 192-202.	2.7	13
13	Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes. <i>Cancer Gene Therapy</i> , 2021, 28, 442-454.	4.6	15
14	Oncolytic Adenovirus ORCA-010 Activates Proinflammatory Myeloid Cells and Facilitates T Cell Recruitment and Activation by PD-1 Blockade in Melanoma. <i>Human Gene Therapy</i> , 2021, 32, 178-191.	2.7	7
15	Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers. <i>Cells</i> , 2021, 10, 978.	4.1	16
16	Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control. <i>Frontiers in Immunology</i> , 2021, 12, 674400.	4.8	22
17	Incidence trends in bladder and lung cancers between Denmark, Finland and Sweden may implicate oral tobacco (snuff/snus) as a possible risk factor. <i>BMC Cancer</i> , 2021, 21, 604.	2.6	7
18	Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden. <i>PLoS ONE</i> , 2021, 16, e0253236.	2.5	13

#	ARTICLE	IF	CITATIONS
19	Second Primary Cancers After Gastric Cancer, and Gastric Cancer as Second Primary Cancer. Clinical Epidemiology, 2021, Volume 13, 515-525.	3.0	9
20	Adenovirus Armed With TNF α and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1. Frontiers in Immunology, 2021, 12, 706517.	4.8	13
21	Survival in colon and rectal cancers in Finland and Sweden through 50 years. BMJ Open Gastroenterology, 2021, 8, e000644.	2.7	16
22	Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas—Long-Term Follow Up. Frontiers in Veterinary Science, 2021, 8, 695222.	2.2	5
23	Second Primary Cancers After Liver, Gallbladder and Bile Duct Cancers, and These Cancers as Second Primary Cancers. Clinical Epidemiology, 2021, Volume 13, 683-691.	3.0	6
24	Familial Risks and Proportions Describing Population Landscape of Familial Cancer. Cancers, 2021, 13, 4385.	3.7	20
25	Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1. Cells, 2021, 10, 246.	4.1	21
26	Types of second primary cancer influence overall survival in cutaneous melanoma. BMC Cancer, 2021, 21, 1123.	2.6	3
27	Incidence, mortality and survival in malignant pleural mesothelioma before and after asbestos in Denmark, Finland, Norway and Sweden. BMC Cancer, 2021, 21, 1189.	2.6	11
28	Second primary cancers in non-Hodgkin lymphoma: Family history and survival. International Journal of Cancer, 2020, 146, 970-976.	5.1	15
29	Second Primary Cancers in Patients with Invasive and In Situ Squamous Cell Skin Carcinoma, Kaposi Sarcoma, and Merkel Cell Carcinoma: Role for Immune Mechanisms?. Journal of Investigative Dermatology, 2020, 140, 48-55.e1.	0.7	7
30	Modulation of the tumor microenvironment with an oncolytic adenovirus for effective T-cell therapy and checkpoint inhibition. Methods in Enzymology, 2020, 635, 205-230.	1.0	9
31	Cancer Predisposition Genes in Cancer-Free Families. Cancers, 2020, 12, 2770.	3.7	2
32	Informing patients about their mutation tests: CDKN2A c.256G>A in melanoma as an example. Hereditary Cancer in Clinical Practice, 2020, 18, 15.	1.5	3
33	Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor. Cancer Medicine, 2020, 9, 8258-8265.	2.8	9
34	<p>Incidence Differences Between First Primary Cancers and Second Primary Cancers Following Skin Squamous Cell Carcinoma as Etiological Clues</p>. Clinical Epidemiology, 2020, Volume 12, 857-864.	3.0	4
35	Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not. European Urology Open Science, 2020, 22, 61-73.	0.4	11
36	Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors. Molecular Therapy - Oncolytics, 2020, 17, 47-60.	4.4	35

#	ARTICLE	IF	CITATIONS
37	<p>Second Primary Cancers in Melanoma Patients Critically Shorten Survival</p>. Clinical Epidemiology, 2020, Volume 12, 105-112.	3.0	3
38	Oncolytic viruses for cancer immunotherapy. Journal of Hematology and Oncology, 2020, 13, 84.	17.0	166
39	Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition. Oncoimmunology, 2020, 9, 1761229.	4.6	22
40	Association between tumor characteristics and second primary cancers with cutaneous melanoma survival: A nationwide cohort study. Pigment Cell and Melanoma Research, 2020, 33, 625-632.	3.3	3
41	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
42	Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity. , 2020, 8, e000188.		45
43	TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling. Cells, 2020, 9, 798.	4.1	26
44	Constitutively active GSK3 ² as a means to bolster dendritic cell functionality in the face of tumour-mediated immune suppression. Oncoimmunology, 2019, 8, e1631119.	4.6	8
45	Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension. European Urology, 2019, 76, 586-595.	1.9	68
46	Familial Associations of Colon and Rectal Cancers With Other Cancers. Diseases of the Colon and Rectum, 2019, 62, 189-195.	1.3	5
47	Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy Constructs. Human Gene Therapy, 2019, 30, 740-752.	2.7	3
48	Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia. British Journal of Haematology, 2019, 185, 232-239.	2.5	34
49	Types of second primary cancers influence survival in chronic lymphocytic and hairy cell leukemia patients. Blood Cancer Journal, 2019, 9, 40.	6.2	7
50	Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.. Expert Opinion on Biological Therapy, 2019, 19, 443-455.	3.1	26
51	Second primary cancer after female breast cancer: Familial risks and cause of death. Cancer Medicine, 2019, 8, 400-407.	2.8	13
52	Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy. Molecular Therapy - Oncolytics, 2018, 9, 41-50.	4.4	8
53	Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI Insight, 2018, 3, .	5.0	191
54	Familial Risks and Mortality in Second Primary Cancers in Melanoma. JNCI Cancer Spectrum, 2018, 2, pky068.	2.9	12

#	ARTICLE	IF	CITATIONS
55	Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus. <i>Molecular Therapy - Oncolytics</i> , 2018, 11, 109-121.	4.4	47
56	Second primary cancers in non-Hodgkin lymphoma: Bidirectional analyses suggesting role for immune dysfunction. <i>International Journal of Cancer</i> , 2018, 143, 2449-2457.	5.1	22
57	Risk of second primary cancer following myeloid neoplasia and risk of myeloid neoplasia as second primary cancer: a nationwide, observational follow up study in Sweden. <i>Lancet Haematology</i> , 2018, 5, e368-e377.	4.6	14
58	Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy. <i>Molecular Therapy</i> , 2018, 26, 2243-2254.	8.2	39
59	Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System. <i>Current Cancer Drug Targets</i> , 2018, 18, 124-138.	1.6	13
60	CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy. <i>Onc Immunology</i> , 2018, 7, e1490856.	4.6	28
61	Multiple myeloma: family history and mortality in second primary cancers. <i>Blood Cancer Journal</i> , 2018, 8, 75.	6.2	5
62	Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients. <i>Oncotarget</i> , 2018, 9, 6320-6335.	1.8	10
63	Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models. <i>Cancer Immunology Research</i> , 2017, 5, 157-169.	3.4	36
64	Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy. <i>Molecular Therapy - Oncolytics</i> , 2017, 4, 77-86.	4.4	88
65	Risk of other Cancers in Families with Melanoma: Novel Familial Links. <i>Scientific Reports</i> , 2017, 7, 42601.	3.3	23
66	Common cancers share familial susceptibility: implications for cancer genetics and counselling. <i>Journal of Medical Genetics</i> , 2017, 54, 248-253.	3.2	12
67	Genetics of gallbladder cancer. <i>Lancet Oncology</i> , 2017, 18, e296.	10.7	9
68	Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy. <i>International Journal of Cancer</i> , 2017, 141, 1458-1468.	5.1	20
69	Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy. <i>Onc Immunology</i> , 2017, 6, e1265717.	4.6	25
70	Concordant and discordant familial cancer: Familial risks, proportions and population impact. <i>International Journal of Cancer</i> , 2017, 140, 1510-1516.	5.1	57
71	Familial associations of male breast cancer with other cancers. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 897-902.	2.5	7
72	Other cancers in lung cancer families are overwhelmingly smoking-related cancers. <i>ERJ Open Research</i> , 2017, 3, 00006-2017.	2.6	3

#	ARTICLE	IF	CITATIONS
73	Familial associations of female breast cancer with other cancers. International Journal of Cancer, 2017, 141, 2253-2259.	5.1	19
74	TILT Biotherapeutics. Human Vaccines and Immunotherapeutics, 2017, 13, 970-971.	3.3	1
75	Familial Associations of Colorectal Cancer with Other Cancers. Scientific Reports, 2017, 7, 5243.	3.3	6
76	Familial Associations Between Prostate Cancer and Other Cancers. European Urology, 2017, 71, 162-165.	1.9	19
77	Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 – Support for clinical studies on advanced cancer treatment. PLoS ONE, 2017, 12, e0182715.	2.5	34
78	Metastatic spread in patients with gastric cancer. Oncotarget, 2016, 7, 52307-52316.	1.8	272
79	Location of metastases in cancer of unknown primary are not random and signal familial clustering. Scientific Reports, 2016, 6, 22891.	3.3	14
80	T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNF α Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma. Journal of Immunotherapy, 2016, 39, 343-354.	2.4	21
81	Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy. Molecular Therapy, 2016, 24, 1323-1332.	8.2	28
82	Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer. Molecular Cancer Therapeutics, 2016, 15, 2259-2269.	4.1	31
83	The epidemiology of metastases in neuroendocrine tumors. International Journal of Cancer, 2016, 139, 2679-2686.	5.1	233
84	Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity. Molecular Therapy - Oncolytics, 2016, 3, 16002.	4.4	32
85	Patterns of metastasis in colon and rectal cancer. Scientific Reports, 2016, 6, 29765.	3.3	652
86	Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers. , 2016, 4, 17.		155
87	Syngeneic Syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting. Oncoimmunology, 2016, 5, e1136046.	4.6	17
88	Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus. Molecular Therapy, 2016, 24, 175-183.	8.2	26
89	Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer. Oncoimmunology, 2016, 5, e1078057.	4.6	29
90	Adenoviral Delivery of Tumor Necrosis Factor α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma. Molecular Therapy, 2016, 24, 1435-1443.	8.2	37

#	ARTICLE	IF	CITATIONS
91	Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: results <i>in vitro</i> , in rodents and in humans. International Journal of Cancer, 2015, 137, 1775-1783.	5.1	41
92	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Frontiers in Immunology, 2015, 6, 588.	4.8	317
93	Incomplete but Infectious Vaccinia Virions Are Produced in the Absence of Oncolysis in Feline SCCF1 Cells. PLoS ONE, 2015, 10, e0120496.	2.5	4
94	T-cell Subsets in Peripheral Blood and Tumors of Patients Treated With Oncolytic Adenoviruses. Molecular Therapy, 2015, 23, 964-973.	8.2	11
95	Immunological Effects of a Tumor Necrosis Factor Alpha-“Armed Oncolytic Adenovirus. Human Gene Therapy, 2015, 26, 134-144.	2.7	42
96	Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy. OncoImmunology, 2015, 4, e989771.	4.6	47
97	Case-“Control Estimation of the Impact of Oncolytic Adenovirus on the Survival of Patients With Refractory Solid Tumors. Molecular Therapy, 2015, 23, 321-329.	8.2	14
98	Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor. Cancer Immunology Research, 2015, 3, 915-925.	3.4	61
99	Attenuated Semliki Forest virus for cancer treatment in dogs: safety assessment in two laboratory Beagles. BMC Veterinary Research, 2015, 11, 170.	1.9	17
100	Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues. Molecular Therapy, 2015, 23, 1641-1652.	8.2	23
101	GM-CSF-armed vaccinia virus induces an antitumor immune response. International Journal of Cancer, 2015, 136, 1065-1072.	5.1	23
102	Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma. International Journal of Cancer, 2015, 136, 945-954.	5.1	51
103	Favorable Alteration of Tumor Microenvironment by Immunomodulatory Cytokines for Efficient T-Cell Therapy in Solid Tumors. PLoS ONE, 2015, 10, e0131242.	2.5	38
104	Immunological data from cancer patients treated with Ad5/3-E2F-1 ²⁴ -GM-CSF suggests utility for tumor immunotherapy. Oncotarget, 2015, 6, 4467-4481.	1.8	63
105	Oncolytic Viruses for Treatment of Cancer. , 2015, , 185-200.		0
106	Consensus guidelines for the detection of immunogenic cell death. OncoImmunology, 2014, 3, e955691.	4.6	686
107	In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders. International Journal of Cancer, 2014, 134, 2878-2890.	5.1	13
108	Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8 ⁺ T-cell response, prominent infiltration of CD8 ⁺ lymphocytes and Th1 type polarization. OncoImmunology, 2014, 3, e958937.	4.6	39

#	ARTICLE	IF	CITATIONS
109	Oncolytic Adenoviruses in the Treatment of Cancer in Humans. , 2014, , 153-170.		0
110	Oncolytic Immunotherapy: Where Are We Clinically?. Scientifica, 2014, 2014, 1-7.	1.7	13
111	Collection and Use of Family History in Oncology Clinics. Journal of Clinical Oncology, 2014, 32, 3344-3345.	1.6	4
112	Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. International Journal of Cancer, 2014, 135, 720-730.	5.1	36
113	Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy. Molecular Therapy - Oncolytics, 2014, 1, 14008.	4.4	19
114	Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy. Molecular Therapy - Oncolytics, 2014, 1, 14006.	4.4	8
115	Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory Beagles. Molecular Therapy - Oncolytics, 2014, 1, 14002.	4.4	11
116	Triweekly docetaxel versus biweekly docetaxel as a treatment for advanced castration resistant prostate cancer: Quality of life analysis.. Journal of Clinical Oncology, 2014, 32, 23-23.	1.6	2
117	Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment. Journal of Translational Medicine, 2013, 11, 193.	4.4	13
118	Resistance to Two Heterologous Neurotropic Oncolytic Viruses, Semliki Forest Virus and Vaccinia Virus, in Experimental Glioma. Journal of Virology, 2013, 87, 2363-2366.	3.4	19
119	Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients. Molecular Therapy, 2013, 21, 1212-1223.	8.2	146
120	Oncolytic Virotherapy Trials Letter. Clinical Cancer Research, 2013, 19, 4541-4542.	7.0	19
121	Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF Coding Oncolytic Adenovirus. Clinical Cancer Research, 2013, 19, 2734-2744.	7.0	150
122	[¹⁸ F]-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography in Response Evaluation of Oncolytic Adenovirus Treatments of Patients with Advanced Cancer. Human Gene Therapy, 2013, 24, 1029-1041.	2.7	23
123	Mutation of the Fiber Shaft Heparan Sulphate Binding Site of a 5/3 Chimeric Adenovirus Reduces Liver Tropism. PLoS ONE, 2013, 8, e60032.	2.5	8
124	Anti-Tumor Activity of a miR-199-dependent Oncolytic Adenovirus. PLoS ONE, 2013, 8, e73964.	2.5	53
125	A New Human DSG2-Transgenic Mouse Model for Studying the Tropism and Pathology of Human Adenoviruses. Journal of Virology, 2012, 86, 6286-6302.	3.4	45
126	Ad3-hTERT-E1A, a Fully Serotype 3 Oncolytic Adenovirus, in Patients With Chemotherapy Refractory Cancer. Molecular Therapy, 2012, 20, 1821-1830.	8.2	64

#	ARTICLE	IF	CITATIONS
127	Oncolytic adenoviruses. <i>OncolImmunology</i> , 2012, 1, 979-981.	4.6	31
128	Portrait of a Leader in Immunotherapeutics. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1018-1021.	3.3	3
129	Verapamil Results in Increased Blood Levels of Oncolytic Adenovirus in Treatment of Patients With Advanced Cancer. <i>Molecular Therapy</i> , 2012, 20, 221-229.	8.2	33
130	Oncolytic Viruses for Induction of Anti-Tumor Immunity. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 1750-1760.	1.6	56
131	An Oncolytic Adenovirus Enhanced for Toll-like Receptor 9 Stimulation Increases Antitumor Immune Responses and Tumor Clearance. <i>Molecular Therapy</i> , 2012, 20, 2076-2086.	8.2	84
132	Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients. <i>Cancer Research</i> , 2012, 72, 1621-1631.	0.9	117
133	Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus. <i>Cancer Research</i> , 2012, 72, 2327-2338.	0.9	144
134	Oncolytic Adenoviruses for Cancer Immunotherapy. <i>Advances in Cancer Research</i> , 2012, 115, 265-318.	5.0	61
135	Radiation-Induced Upregulation of Gene Expression From Adenoviral Vectors Mediated by DNA Damage Repair and Regulation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 376-384.	0.8	5
136	A phase II trial of gefitinib in patients with rising PSA following radical prostatectomy or radiotherapy. <i>Acta Oncol</i> , 2012, 51, 130-133.	1.8	7
137	Treatment of Chemotherapy-Refractory Cancer in the Advanced Therapy Access Program. <i>Molecular Therapy</i> , 2012, 20, 1654-1655.	8.2	8
138	SPECT/CT Imaging of hNIS -Expression after Intravenous Delivery of an Oncolytic Adenovirus and 131I. <i>PLoS ONE</i> , 2012, 7, e32871.	2.5	21
139	Effects of capsid-modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer. <i>International Journal of Cancer</i> , 2012, 131, 253-263.	5.1	10
140	Integrin targeted oncolytic adenoviruses Ad5-ΔD24-EGD and Ad5-EGD-ΔD24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. <i>International Journal of Cancer</i> , 2012, 130, 1937-1947.	5.1	82
141	CGTC-102 (Ad5/3-D24-GMCSF), a novel oncolytic adenovirus, in patients with refractory solid tumors: Experience from an advanced therapy access program.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13035-e13035.	1.6	0
142	Safety of Glucocorticoids in Cancer Patients Treated with Oncolytic Adenoviruses. <i>Molecular Pharmaceutics</i> , 2011, 8, 93-103.	4.6	4
143	Oncolytic vaccinia virus for the treatment of cancer. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 595-608.	3.1	78
144	Oncolytic Adenoviruses for the Treatment of Human Cancer: Focus on Translational and Clinical Data. <i>Molecular Pharmaceutics</i> , 2011, 8, 12-28.	4.6	106

#	ARTICLE	IF	CITATIONS
145	A New Generation of Serotype Chimeric Infectivity-Enhanced Conditionally Replicative Adenovirals: The Safety Profile of Ad5/3- \hat{f} ²⁴ in Advance of a Phase I Clinical Trial in Ovarian Cancer Patients. Human Gene Therapy, 2011, 22, 821-828.	2.7	19
146	In vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments. Annals of Medicine, 2011, 43, 151-163.	3.8	17
147	Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nature Medicine, 2011, 17, 96-104.	30.7	348
148	Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients. Journal of Gene Medicine, 2011, 13, 253-261.	2.8	30
149	Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus. Molecular Therapy, 2011, 19, 1737-1746.	8.2	141
150	Sodium Iodide Symporter SPECT Imaging of a Patient Treated With Oncolytic Adenovirus Ad5/3- \hat{f} ²⁴ -hNIS. Molecular Therapy, 2011, 19, 629-631.	8.2	20
151	Induction of Interferon Pathways Mediates In Vivo Resistance to Oncolytic Adenovirus. Molecular Therapy, 2011, 19, 1858-1866.	8.2	42
152	Multimerization of Adenovirus Serotype 3 Fiber Knob Domains Is Required for Efficient Binding of Virus to Desmoglein 2 and Subsequent Opening of Epithelial Junctions. Journal of Virology, 2011, 85, 6390-6402.	3.4	75
153	Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1. Clinical Cancer Research, 2010, 16, 2540-2549.	7.0	37
154	Oncolytic adenovirus research and applications. Future Virology, 2010, 5, 745-761.	1.8	3
155	Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir. Journal of Gene Medicine, 2010, 12, 435-445.	2.8	36
156	Adenoviral E4orf3 and E4orf6 Proteins, But Not E1B55K, Increase Killing of Cancer Cells by Radiotherapy in vivo. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1201-1209.	0.8	3
157	Defects in Innate Immunity Render Breast Cancer Initiating Cells Permissive to Oncolytic Adenovirus. PLoS ONE, 2010, 5, e13859.	2.5	25
158	Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors. Clinical Cancer Research, 2010, 16, 3035-3043.	7.0	97
159	Serotype Chimeric Human Adenoviruses for Cancer Gene Therapy. Viruses, 2010, 2, 2196-2212.	3.3	17
160	Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF. Molecular Therapy, 2010, 18, 1874-1884.	8.2	201
161	Oncolytic adenovirus treatment of a patient with refractory neuroblastoma. Acta Oncologica, 2010, 49, 120-122.	1.8	32
162	Adenoviruses with an \hat{f} ² integrin targeting moiety in the fiber shaft or the HI-loop increase tumor specificity without compromising antitumor efficacy in magnetic resonance imaging of colorectal cancer metastases. Journal of Translational Medicine, 2010, 8, 80.	4.4	3

#	ARTICLE	IF	CITATIONS
163	Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures. <i>European Journal of Cancer</i> , 2010, 46, 625-635.	2.8	25
164	Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients. <i>Cancer Research</i> , 2010, 70, 4297-4309.	0.9	197
165	Calcium Gluconate in Phosphate Buffered Saline Increases Gene Delivery with Adenovirus Type 5. <i>PLoS ONE</i> , 2010, 5, e13103.	2.5	2
166	Targeted Radiotherapy for Prostate Cancer with an Oncolytic Adenovirus Coding for Human Sodium Iodide Symporter. <i>Clinical Cancer Research</i> , 2009, 15, 5396-5403.	7.0	39
167	Serotype Chimeric and Fiber-Mutated Adenovirus Ad5/19p-HIT for Targeting Renal Cancer and Untargeting the Liver. <i>Human Gene Therapy</i> , 2009, 20, 611-620.	2.7	17
168	Replacement of Adenovirus Type 5 Fiber Shaft Heparan Sulfate Proteoglycan-Binding Domain with RGD for Improved Tumor Infectivity and Targeting. <i>Human Gene Therapy</i> , 2009, 20, 1214-1221.	2.7	46
169	Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation. <i>International Journal of Cancer</i> , 2009, 125, 2441-2449.	5.1	32
170	Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells. <i>Journal of Gene Medicine</i> , 2009, 11, 966-977.	2.8	30
171	Discovery of a new PCC-mediated stereoselective oxidative spiroketalization process. An access to a new type of poly-THF spiroketal compound displaying anticancer activity. <i>Organic and Biomolecular Chemistry</i> , 2009, 7, 3036.	2.8	13
172	The cyclooxygenase 2 promoter is induced in nontarget cells following adenovirus infection, but an AU-rich 3' untranslated region destabilization element can increase specificity. <i>Journal of Gene Medicine</i> , 2008, 10, 744-753.	2.8	3
173	Oncolytic adenovirus Ad5/3-124 and chemotherapy for treatment of orthotopic ovarian cancer. <i>Gynecologic Oncology</i> , 2008, 108, 166-172.	1.4	38
174	Cancer, stem cells, and oncolytic viruses. <i>Annals of Medicine</i> , 2008, 40, 496-505.	3.8	40
175	Tissue-Specific Promoters Active in CD44+CD24 ^{low} Breast Cancer Cells. <i>Cancer Research</i> , 2008, 68, 5533-5539.	0.9	100
176	Generation of a Conditionally Replicating Adenovirus Based on Targeted Destruction of E1A mRNA by a Cell Type-Specific MicroRNA. <i>Journal of Virology</i> , 2008, 82, 11009-11015.	3.4	116
177	Virotherapy as An Approach Against Cancer Stem Cells. <i>Current Gene Therapy</i> , 2008, 8, 88-96.	2.0	28
178	Systemic Therapy for Cervical Cancer with Potentially Regulatable Oncolytic Adenoviruses. <i>PLoS ONE</i> , 2008, 3, e2917.	2.5	11
179	Oncolytic Viruses for Treatment of Cancer. , 2008, , .		0
180	Oncolytic Adenoviruses Kill Breast Cancer Initiating CD44+CD24 ^{low} /Low Cells. <i>Molecular Therapy</i> , 2007, 15, 2088-2093.	8.2	85

#	ARTICLE	IF	CITATIONS
181	Human Mesenchymal Stem Cells Lack Tumor Tropism but Enhance the Antitumor Activity of Oncolytic Adenoviruses in Orthotopic Lung and Breast Tumors. <i>Human Gene Therapy</i> , 2007, 18, 627-641.	2.7	129
182	Treatment of prostate cancer with Ad5/3 β 24hCC allows non-invasive detection of the magnitude and persistence of virus replication in vivo. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 742-751.	4.1	36
183	Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2728-2736.	4.1	44
184	Gene therapy of gynaecological diseases. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 1347-1361.	3.1	16
185	Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer. <i>International Journal of Cancer</i> , 2007, 121, 165-174.	5.1	35
186	Chlorpromazine and apigenin reduce adenovirus replication and decrease replication associated toxicity. <i>Journal of Gene Medicine</i> , 2007, 9, 3-9.	2.8	29
187	A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5 β 24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapy. <i>International Journal of Molecular Medicine</i> , 2006, 18, 751.	4.0	4
188	Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer. <i>Cancer</i> , 2006, 107, 1578-1588.	4.1	33
189	Infectivity-Enhanced Adenoviruses Deliver Efficacy in Clinical Samples and Orthotopic Models of Disseminated Gastric Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 3137-3144.	7.0	40
190	Triple-Targeted Oncolytic Adenoviruses Featuring the Cox2 Promoter, E1A Transcomplementation, and Serotype Chimerism for Enhanced Selectivity for Ovarian Cancer Cells. <i>Molecular Therapy</i> , 2006, 14, 164-174.	8.2	61
191	Gene Transfer Approaches for Gynecological Diseases. <i>Molecular Therapy</i> , 2006, 14, 154-163.	8.2	35
192	A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5Delta24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapy. <i>International Journal of Molecular Medicine</i> , 2006, 18, 751-9.	4.0	18
193	Adenoviruses with an RGD-4C modification of the fiber knob elicit a neutralizing antibody response but continue to allow enhanced gene delivery. <i>Gynecologic Oncology</i> , 2005, 96, 341-348.	1.4	15
194	Adenoviruses for treatment of cancer. <i>Annals of Medicine</i> , 2005, 37, 33-43.	3.8	75
195	An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism. <i>Virology</i> , 2004, 324, 103-116.	2.4	67
196	Modified adenoviruses for cancer gene therapy. <i>International Journal of Cancer</i> , 2004, 110, 475-480.	5.1	119
197	Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer. <i>International Journal of Cancer</i> , 2004, 111, 303-309.	5.1	42
198	Evaluation of tissue-specific promoters in carcinomas of the cervix uteri. <i>Journal of Gene Medicine</i> , 2004, 6, 1281-1289.	2.8	22

#	ARTICLE	IF	CITATIONS
199	Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy. Journal of Gene Medicine, 2004, 6, 1333-1342.	2.8	34
200	Tissue-specific promoters for cancer gene therapy. Expert Opinion on Biological Therapy, 2004, 4, 683-696.	3.1	91
201	Tissue-specific promoters for cancer gene therapy. Expert Opinion on Biological Therapy, 2004, 4, 683-696.	3.1	1
202	The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy. Journal of Gene Medicine, 2003, 5, 300-310.	2.8	61
203	Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids. Cancer Gene Therapy, 2003, 10, 377-387.	4.6	26
204	Production of an EGFR targeting molecule from a conditionally replicating adenovirus impairs its oncolytic potential. Cancer Gene Therapy, 2003, 10, 583-588.	4.6	26
205	A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Molecular Therapy, 2003, 7, 163-173.	8.2	93
206	Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Molecular Therapy, 2003, 8, 449-458.	8.2	159
207	Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. Cancer Research, 2003, 63, 847-53.	0.9	73
208	Gene Transfer to Ovarian Cancer Versus Normal Tissues with Fiber-Modified Adenoviruses. Molecular Therapy, 2002, 5, 695-704.	8.2	170
209	In Vivo Molecular Chemotherapy and Noninvasive Imaging With an Infectivity-Enhanced Adenovirus. Journal of the National Cancer Institute, 2002, 94, 741-749.	6.3	75
210	Adenoviruses in Oncology. BioDrugs, 2002, 16, 77-87.	4.6	48
211	Serum and Ascites Neutralizing Antibodies in Ovarian Cancer Patients Treated with Intraperitoneal Adenoviral Gene Therapy. Human Gene Therapy, 2002, 13, 1505-1514.	2.7	38
212	Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clinical Cancer Research, 2002, 8, 275-80.	7.0	191
213	Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Research, 2002, 62, 1266-70.	0.9	115
214	The flt-1 promoter for transcriptional targeting of teratocarcinoma. Cancer Research, 2002, 62, 1271-4.	0.9	22
215	An Adenovirus with Enhanced Infectivity Mediates Molecular Chemotherapy of Ovarian Cancer Cells and Allows Imaging of Gene Expression. Molecular Therapy, 2001, 4, 223-231.	8.2	119